Prism Medico & Pharmacy Limited announced significant corporate developments following its board meeting held on February 23, 2026. The board approved a comprehensive fundraising plan and key amendments to facilitate future capital raising activities.

Board Meeting Outcomes

The board meeting, which commenced at 01:00 P.M. and concluded at 06:30 P.M. on February 23, 2026, resulted in several important approvals. The directors considered and approved the alteration of Article 15 of the Articles of Association by inserting a new clause to empower the company to issue further securities through various methods including preferential offers or private placements.

The board also approved the issuance of securities to both promoter and non-promoter categories, subject to shareholder approval at the upcoming Extraordinary General Meeting.

Securities Issuance Details

The issue price of Rs. 20 per equity share and convertible warrant has been calculated in accordance with SEBI ICDR Regulations and is not lower than the floor price determined under Regulation 164 read with 166A of Chapter V of SEBI ICDR Regulations.

Convertible Warrants Structure

The convertible warrants carry specific terms for conversion and payment. Minimum 25% of the warrant price would be payable upfront at the time of application, while the balance 75% shall be payable at the time of conversion into equity shares.

Key warrant features include:

• Conversion Ratio: 1:1 (each warrant converts to one equity share)
• Conversion Period: 18 months from allotment date
• Flexibility: Conversion possible in one or more tranches
• Lapse Condition: Warrants lapse if not exercised within stipulated period

Investor Allocation

The allocation includes seven specific investors, with Symbiosis Pharmaceuticals Private Limited and Galaxy Vitacare Private Limited representing the promoter category. The non-promoter category comprises five investors including Sejal S Nashatar, Harsh Jentibhai Rupareliya, Shilpa Harsh Rupareliya, Raju Tyagi, and Dharmender Kharb.

Extraordinary General Meeting

The board approved convening an Extraordinary General Meeting of members on Friday, March 20, 2026, through Video Conferencing and Other Audio-Visual Means as per relevant MCA and SEBI circulars. The EGM will seek shareholders' approval for the proposed securities issuance and Articles of Association amendments.

Mr. Mast Ram Chechi, proprietor of M/s. M.R. Chechi and Associates, Practicing Company Secretaries, has been appointed as Scrutinizer to oversee the e-voting process in a fair and transparent manner.

Shareholding Impact

Post-allotment, the total number of investors will increase significantly, with the promoter holding expected to change from the current 22.61% to 74.72% of the expanded share capital. The preferential issue represents a substantial expansion of the company's equity base and provides significant capital for future growth initiatives.

Prism Medico & Pharmacy Limited has announced its unaudited standalone financial results for the quarter ended December 31, 2025, following the board meeting held on February 13, 2026. The company reported a net loss of ₹1.34 lakhs for Q3FY26, compared to a net loss of ₹0.96 lakhs in the corresponding quarter of the previous year.

Financial Performance Overview

The company's financial performance showed mixed results during the third quarter. Revenue from operations declined significantly to ₹7.10 lakhs in Q3FY26 from ₹20.86 lakhs in Q3FY25, representing a substantial year-on-year decrease. Total income, including other income of ₹0.69 lakhs, reached ₹7.79 lakhs compared to ₹21.21 lakhs in the previous year's corresponding quarter.

Expense Analysis and Cost Structure

Total expenses for the quarter amounted to ₹9.13 lakhs, down from ₹22.11 lakhs in Q3FY25. Cost of material consumed decreased to ₹4.25 lakhs from ₹15.22 lakhs year-on-year. Employee benefit expenses remained relatively stable at ₹1.19 lakhs compared to ₹1.13 lakhs in the previous year. Other expenses reduced significantly to ₹3.61 lakhs from ₹5.63 lakhs in Q3FY25.

Year-to-Date Performance

For the nine-month period ended December 31, 2025, the company demonstrated contrasting performance with total income of ₹218.60 lakhs and a net profit of ₹55.91 lakhs. This positive year-to-date performance indicates stronger performance in earlier quarters of the financial year.

Board Meeting Details and Regulatory Compliance

The board meeting was conducted at the company's registered office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030, commencing at 01:00 P.M. and concluding at 05:30 P.M. The results were approved by the Board of Directors and have been duly reviewed by the Audit Committee in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Stock Exchange Notifications

Prism Medico and Pharmacy Limited has notified both BSE Limited (Scrip Code: 512217) and Metropolitan Stock Exchange of India Limited (Symbol: PRISMMEI) about the financial results. The company maintains its ISIN as INE730E01016 and operates under CIN: L24100HP2002PLC009299. The results were prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by auditors Garg Mendiratta & Associates, Chartered Accountants.